Urothelial cancer | PharmaTimes

First treatment for common bladder cancer recommended by NICE

Ella Day — Thu, 10 Apr 2025 11:22:53 +0000

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration

Hundreds of urothelial cancer patients to receive new treatment

John Pinching — Thu, 07 Apr 2022 12:14:00 +0000

NICE recommends avelumab as treatment for adults with locally advanced or metastatic urothelial cancer

Four new medicines available via NHS Scotland

Selina McKee — Tue, 11 Sep 2018 10:25:00 +0000

The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.

Final NICE no for BMS’ Opdivo in urothelial carcinoma

Selina McKee — Wed, 04 Jul 2018 23:07:00 +0000

The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

NICE rejects Roche’s Tecentriq for pre-treated urothelial cancer

Selina McKee — Fri, 22 Dec 2017 09:37:00 +0000

Cost regulators for NHS treatments in England and Wales have turned down Roche’s Tecentriq for patients who have already received prior treatment for metastatic urothelial cancer.

NICE back Roche’s Tecentriq for CDF

Selina McKee — Wed, 01 Nov 2017 11:07:00 +0000

The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.

NICE no for Opdivo in urothelial carcinoma

Selina McKee — Fri, 20 Oct 2017 10:10:00 +0000

The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

NICE leans towards a ‘no’ for Keytruda in urothelial cancer

Selina McKee — Fri, 04 Aug 2017 08:33:00 +0000

Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as a treatment for locally advanced or metastatic urothelial cancer.

Priority review for Merck, Pfizer’s avelumab in urothelial cancer

Selina McKee — Wed, 01 Mar 2017 11:08:00 +0000

US regulators have agreed to undertake a priority review Merck and Pfizer's avelumab as a potential treatment for metastatic urothelial carcinoma (mUC).